Thermo Fisher Scientific Inc. (NYSE: TMO) Stock Competitors & Peer Comparison
See TMO's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for TMO and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| TMO | $694.76 | +2.63% | 257.5B | 30.00 | $23.16 | +0.27% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| DHR | $230.25 | +1.73% | 161.9B | 28.86 | $7.98 | +0.66% |
| IDXX | $676.04 | +0.79% | 53.3B | 47.54 | $14.22 | N/A |
| A | $174.76 | +1.73% | 49.3B | 30.08 | $5.81 | +0.59% |
| WAT | $457.60 | +1.00% | 44.9B | 33.45 | $13.68 | N/A |
| IQV | $271.83 | +2.62% | 44.8B | 22.40 | $12.13 | N/A |
| NTRA | $310.67 | -14.59% | 44.7B | -235.14 | -$1.32 | N/A |
| MTD | $1,722.15 | +2.57% | 34.5B | 39.56 | $43.51 | N/A |
| ILMN | $213.13 | +2.47% | 32.2B | 42.36 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
TMO vs DHR-PB Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, TMO's ROE is +0.13%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DHR-PB's competition here
Danaher Corporation (NYSE: DHR)
TMO vs DHR Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, DHR has a market cap of 161.9B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while DHR trades at $230.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas DHR's P/E ratio is 28.86. In terms of profitability, TMO's ROE is +0.13%, compared to DHR's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
TMO vs IDXX Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, IDXX has a market cap of 53.3B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while IDXX trades at $676.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas IDXX's P/E ratio is 47.54. In terms of profitability, TMO's ROE is +0.13%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, TMO is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for TMO.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
TMO vs A Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, A has a market cap of 49.3B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while A trades at $174.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas A's P/E ratio is 30.08. In terms of profitability, TMO's ROE is +0.13%, compared to A's ROE of +0.20%. Regarding short-term risk, TMO is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for TMO.Check A's competition here
Waters Corporation (NYSE: WAT)
TMO vs WAT Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, WAT has a market cap of 44.9B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while WAT trades at $457.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas WAT's P/E ratio is 33.45. In terms of profitability, TMO's ROE is +0.13%, compared to WAT's ROE of +0.01%. Regarding short-term risk, TMO is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for TMO.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
TMO vs IQV Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, IQV has a market cap of 44.8B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while IQV trades at $271.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas IQV's P/E ratio is 22.40. In terms of profitability, TMO's ROE is +0.13%, compared to IQV's ROE of +0.22%. Regarding short-term risk, TMO is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for TMO.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
TMO vs NTRA Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, NTRA has a market cap of 44.7B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while NTRA trades at $310.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas NTRA's P/E ratio is -235.14. In terms of profitability, TMO's ROE is +0.13%, compared to NTRA's ROE of -0.09%. Regarding short-term risk, TMO is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NTRA's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
TMO vs MTD Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, MTD has a market cap of 34.5B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while MTD trades at $1,722.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas MTD's P/E ratio is 39.56. In terms of profitability, TMO's ROE is +0.13%, compared to MTD's ROE of +149.66%. Regarding short-term risk, TMO is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MTD's competition here
Illumina, Inc. (NASDAQ: ILMN)
TMO vs ILMN Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, ILMN has a market cap of 32.2B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while ILMN trades at $213.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas ILMN's P/E ratio is 42.36. In terms of profitability, TMO's ROE is +0.13%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, TMO is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for TMO.Check ILMN's competition here
Labcorp Holdings Inc. (NYSE: LH)
TMO vs LH Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, LH has a market cap of 29.8B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while LH trades at $366.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas LH's P/E ratio is 21.76. In terms of profitability, TMO's ROE is +0.13%, compared to LH's ROE of +0.12%. Regarding short-term risk, TMO is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
TMO vs DGX Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, DGX has a market cap of 28.2B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while DGX trades at $255.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas DGX's P/E ratio is 25.22. In terms of profitability, TMO's ROE is +0.13%, compared to DGX's ROE of +0.15%. Regarding short-term risk, TMO is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
TMO vs GH Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, GH has a market cap of 20.3B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while GH trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas GH's P/E ratio is -43.33. In terms of profitability, TMO's ROE is +0.13%, compared to GH's ROE of +2.49%. Regarding short-term risk, TMO is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for TMO.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
TMO vs EXAS Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas EXAS's P/E ratio is -95.37. In terms of profitability, TMO's ROE is +0.13%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, TMO is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for TMO.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
TMO vs MEDP Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, MEDP has a market cap of 18.3B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while MEDP trades at $653.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas MEDP's P/E ratio is 36.22. In terms of profitability, TMO's ROE is +0.13%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, TMO is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for TMO.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
TMO vs RVTY Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, RVTY has a market cap of 17.3B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while RVTY trades at $155.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas RVTY's P/E ratio is 29.01. In terms of profitability, TMO's ROE is +0.13%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, TMO is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for TMO.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
TMO vs ILMNV Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas ILMNV's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to ILMNV's ROE of N/A. Regarding short-term risk, TMO is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for TMO.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
TMO vs CRL Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, CRL has a market cap of 16.2B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while CRL trades at $337.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas CRL's P/E ratio is 34.09. In terms of profitability, TMO's ROE is +0.13%, compared to CRL's ROE of +0.01%. Regarding short-term risk, TMO is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
TMO vs ICLR Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, ICLR has a market cap of 15.3B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while ICLR trades at $204.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas ICLR's P/E ratio is 16.71. In terms of profitability, TMO's ROE is +0.13%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, TMO is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for TMO.Check ICLR's competition here
PerkinElmer, Inc. (NYSE: PKI)
TMO vs PKI Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas PKI's P/E ratio is 41.45. In terms of profitability, TMO's ROE is +0.13%, compared to PKI's ROE of +0.04%. Regarding short-term risk, TMO is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PKI's competition here
Qiagen N.V. (NYSE: QGEN)
TMO vs QGEN Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while QGEN trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas QGEN's P/E ratio is 20.79. In terms of profitability, TMO's ROE is +0.13%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, TMO is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for TMO.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
TMO vs RDNT Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, RDNT has a market cap of 6B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while RDNT trades at $76.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas RDNT's P/E ratio is 164.87. In terms of profitability, TMO's ROE is +0.13%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, TMO is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
TMO vs GRAL Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while GRAL trades at $121.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas GRAL's P/E ratio is -12.45. In terms of profitability, TMO's ROE is +0.13%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, TMO is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check GRAL's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
TMO vs BLLN Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while BLLN trades at $113.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas BLLN's P/E ratio is 162.81. In terms of profitability, TMO's ROE is +0.13%, compared to BLLN's ROE of +0.09%. Regarding short-term risk, TMO is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
TMO vs SHC Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, SHC has a market cap of 4.6B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while SHC trades at $16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas SHC's P/E ratio is 16.68. In terms of profitability, TMO's ROE is +0.13%, compared to SHC's ROE of +0.26%. Regarding short-term risk, TMO is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for TMO.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
TMO vs SYNH Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas SYNH's P/E ratio is 61.40. In terms of profitability, TMO's ROE is +0.13%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
TMO vs CDNA Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, CDNA has a market cap of 4.1B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while CDNA trades at $78.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas CDNA's P/E ratio is 93.46. In terms of profitability, TMO's ROE is +0.13%, compared to CDNA's ROE of +0.34%. Regarding short-term risk, TMO is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
TMO vs OLK Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas OLK's P/E ratio is -96.59. In terms of profitability, TMO's ROE is +0.13%, compared to OLK's ROE of -0.07%. Regarding short-term risk, TMO is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for TMO.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
TMO vs NEO Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while NEO trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas NEO's P/E ratio is 129.54. In terms of profitability, TMO's ROE is +0.13%, compared to NEO's ROE of -0.04%. Regarding short-term risk, TMO is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for TMO.Check NEO's competition here
Veracyte, Inc. (NASDAQ: VCYT)
TMO vs VCYT Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, VCYT has a market cap of 1.9B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while VCYT trades at $24.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas VCYT's P/E ratio is 12.07. In terms of profitability, TMO's ROE is +0.13%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, TMO is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
TMO vs WGS Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while WGS trades at $62.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas WGS's P/E ratio is 173.25. In terms of profitability, TMO's ROE is +0.13%, compared to WGS's ROE of -0.39%. Regarding short-term risk, TMO is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for TMO.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
TMO vs PSNL Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while PSNL trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas PSNL's P/E ratio is -14.48. In terms of profitability, TMO's ROE is +0.13%, compared to PSNL's ROE of -0.50%. Regarding short-term risk, TMO is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
TMO vs OPK Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, OPK has a market cap of 1.3B. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while OPK trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas OPK's P/E ratio is -19.17. In terms of profitability, TMO's ROE is +0.13%, compared to OPK's ROE of -0.12%. Regarding short-term risk, TMO is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for TMO.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
TMO vs CSTL Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, CSTL has a market cap of 993.2M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while CSTL trades at $32.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas CSTL's P/E ratio is -49.26. In terms of profitability, TMO's ROE is +0.13%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, TMO is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
TMO vs FLGT Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, FLGT has a market cap of 654.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while FLGT trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas FLGT's P/E ratio is 2378.00. In terms of profitability, TMO's ROE is +0.13%, compared to FLGT's ROE of -0.09%. Regarding short-term risk, TMO is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for TMO.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
TMO vs GRALV Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas GRALV's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to GRALV's ROE of N/A. Regarding short-term risk, TMO is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for TMO.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
TMO vs MYGN Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, MYGN has a market cap of 564.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while MYGN trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas MYGN's P/E ratio is -45.38. In terms of profitability, TMO's ROE is +0.13%, compared to MYGN's ROE of -0.40%. Regarding short-term risk, TMO is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
TMO vs CO Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas CO's P/E ratio is 5.06. In terms of profitability, TMO's ROE is +0.13%, compared to CO's ROE of +0.11%. Regarding short-term risk, TMO is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
TMO vs FLDM Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas FLDM's P/E ratio is -4.74. In terms of profitability, TMO's ROE is +0.13%, compared to FLDM's ROE of +0.26%. Regarding short-term risk, TMO is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for TMO.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
TMO vs XGN Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, XGN has a market cap of 140.5M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while XGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas XGN's P/E ratio is -7.16. In terms of profitability, TMO's ROE is +0.13%, compared to XGN's ROE of -1.22%. Regarding short-term risk, TMO is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check XGN's competition here
Genetron Holdings Limited (NASDAQ: GTH)
TMO vs GTH Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas GTH's P/E ratio is -1.11. In terms of profitability, TMO's ROE is +0.13%, compared to GTH's ROE of -1.01%. Regarding short-term risk, TMO is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
TMO vs GENE Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas GENE's P/E ratio is -38.25. In terms of profitability, TMO's ROE is +0.13%, compared to GENE's ROE of -1.85%. Regarding short-term risk, TMO is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for TMO.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
TMO vs FRNM Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, FRNM has a market cap of 83M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while FRNM trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas FRNM's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to FRNM's ROE of N/A. Regarding short-term risk, TMO is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for TMO.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
TMO vs IMDX Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, IMDX has a market cap of 81.5M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while IMDX trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas IMDX's P/E ratio is -1.67. In terms of profitability, TMO's ROE is +0.13%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, TMO is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check IMDX's competition here
Biodesix, Inc. (NASDAQ: BDSX)
TMO vs BDSX Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, BDSX has a market cap of 69.8M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while BDSX trades at $8.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas BDSX's P/E ratio is -2.71. In terms of profitability, TMO's ROE is +0.13%, compared to BDSX's ROE of -4.42%. Regarding short-term risk, TMO is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BDSX's competition here
Precipio, Inc. (NASDAQ: PRPO)
TMO vs PRPO Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, PRPO has a market cap of 33.5M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while PRPO trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas PRPO's P/E ratio is -28.78. In terms of profitability, TMO's ROE is +0.13%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, TMO is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for TMO.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
TMO vs AKU Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas AKU's P/E ratio is -0.13. In terms of profitability, TMO's ROE is +0.13%, compared to AKU's ROE of -5.32%. Regarding short-term risk, TMO is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for TMO.Check AKU's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
TMO vs BIAF Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, BIAF has a market cap of 17.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while BIAF trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas BIAF's P/E ratio is -0.32. In terms of profitability, TMO's ROE is +0.13%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, TMO is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BIAF's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
TMO vs CEMI Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas CEMI's P/E ratio is -0.63. In terms of profitability, TMO's ROE is +0.13%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, TMO is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for TMO.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
TMO vs ENZ Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas ENZ's P/E ratio is -2.24. In terms of profitability, TMO's ROE is +0.13%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, TMO is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ENZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
TMO vs QUCY Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, QUCY has a market cap of 16.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while QUCY trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas QUCY's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, TMO is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for TMO.Check QUCY's competition here
Psychemedics Corporation (NASDAQ: PMD)
TMO vs PMD Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas PMD's P/E ratio is -5.24. In terms of profitability, TMO's ROE is +0.13%, compared to PMD's ROE of -0.32%. Regarding short-term risk, TMO is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
TMO vs ME Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas ME's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to ME's ROE of -3.47%. Regarding short-term risk, TMO is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for TMO.Check ME's competition here
MDxHealth S.A. (NASDAQ: MDXH)
TMO vs MDXH Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, MDXH has a market cap of 15.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while MDXH trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas MDXH's P/E ratio is -0.22. In terms of profitability, TMO's ROE is +0.13%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, TMO is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MDXH's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
TMO vs MYNZ Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, TMO's ROE is +0.13%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, TMO is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
TMO vs BNR Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, BNR has a market cap of 14.5M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while BNR trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas BNR's P/E ratio is -15.79. In terms of profitability, TMO's ROE is +0.13%, compared to BNR's ROE of -0.13%. Regarding short-term risk, TMO is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
TMO vs CHEK Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas CHEK's P/E ratio is -0.43. In terms of profitability, TMO's ROE is +0.13%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, TMO is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for TMO.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
TMO vs CNTG Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas CNTG's P/E ratio is -0.23. In terms of profitability, TMO's ROE is +0.13%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, TMO is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for TMO.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
TMO vs APDN Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas APDN's P/E ratio is -0.10. In terms of profitability, TMO's ROE is +0.13%, compared to APDN's ROE of -7.23%. Regarding short-term risk, TMO is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for TMO.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
TMO vs NDRA Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while NDRA trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas NDRA's P/E ratio is -0.70. In terms of profitability, TMO's ROE is +0.13%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, TMO is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
TMO vs BIAFW Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, BIAFW has a market cap of 7M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas BIAFW's P/E ratio is 0.75. In terms of profitability, TMO's ROE is +0.13%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, TMO is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
TMO vs NVTA Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas NVTA's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, TMO is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
TMO vs LMDXW Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, TMO is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
TMO vs LMDX Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas LMDX's P/E ratio is -0.01. In terms of profitability, TMO's ROE is +0.13%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, TMO is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for TMO.Check LMDX's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
TMO vs ADVB Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, ADVB has a market cap of 3.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while ADVB trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas ADVB's P/E ratio is -18.32. In terms of profitability, TMO's ROE is +0.13%, compared to ADVB's ROE of +1.22%. Regarding short-term risk, TMO is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
TMO vs DMTK Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas DMTK's P/E ratio is -0.04. In terms of profitability, TMO's ROE is +0.13%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, TMO is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for TMO.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
TMO vs NOTV Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas NOTV's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, TMO is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
TMO vs SQL Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas SQL's P/E ratio is -0.40. In terms of profitability, TMO's ROE is +0.13%, compared to SQL's ROE of -30.46%. Regarding short-term risk, TMO is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for TMO.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
TMO vs AWH Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas AWH's P/E ratio is -0.09. In terms of profitability, TMO's ROE is +0.13%, compared to AWH's ROE of +1.62%. Regarding short-term risk, TMO is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for TMO.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
TMO vs ISPC Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, ISPC has a market cap of 2M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while ISPC trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas ISPC's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, TMO is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for TMO.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
TMO vs HTGM Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas HTGM's P/E ratio is -0.03. In terms of profitability, TMO's ROE is +0.13%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, TMO is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for TMO.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
TMO vs BIOC Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas BIOC's P/E ratio is -0.01. In terms of profitability, TMO's ROE is +0.13%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, TMO is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
TMO vs SQLLW Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, TMO is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
TMO vs WGSWW Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, TMO's ROE is +0.13%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, TMO is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for TMO.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
TMO vs OCDX Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas OCDX's P/E ratio is -42.28. In terms of profitability, TMO's ROE is +0.13%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, TMO is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for TMO.Check OCDX's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
TMO vs PRXL Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas PRXL's P/E ratio is 42.97. In terms of profitability, TMO's ROE is +0.13%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, TMO is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for TMO.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
TMO vs NDRAW Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas NDRAW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, TMO is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
TMO vs DHR-PA Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, TMO's ROE is +0.13%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, TMO is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for TMO.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
TMO vs CHEKZ Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, TMO is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for TMO.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
TMO vs MEUSW Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas MEUSW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, TMO is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
TMO vs BNGOW Comparison November 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, TMO stands at 257.5B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, TMO is priced at $694.76 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
TMO currently has a P/E ratio of 30.00, whereas BNGOW's P/E ratio is N/A. In terms of profitability, TMO's ROE is +0.13%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, TMO is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for TMO.Check BNGOW's competition here